UBS Group AG Purchases 102,338 Shares of Xylem Inc. (NYSE:XYL)

UBS Group AG boosted its position in Xylem Inc. (NYSE:XYL – Get Rating) by 54.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 289,230 shares of the industrial products company’s stock after buying an additional 102,338 shares during the period. UBS Group AG owned approximately 0.16% of Xylem worth $31,980,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Panagora Asset Management Inc. boosted its stake in Xylem by 21.7% during the 1st quarter. Panagora Asset Management Inc. now owns 14,297 shares of the industrial products company’s stock valued at $1,219,000 after purchasing an additional 2,550 shares during the last quarter. Yousif Capital Management LLC boosted its stake in Xylem by 1.5% during the 1st quarter. Yousif Capital Management LLC now owns 27,307 shares of the industrial products company’s stock valued at $2,328,000 after purchasing an additional 416 shares during the last quarter. Blair William & Co. IL boosted its stake in Xylem by 0.5% during the 1st quarter. Blair William & Co. IL now owns 66,243 shares of the industrial products company’s stock valued at $5,648,000 after purchasing an additional 299 shares during the last quarter. Sei Investments Co. boosted its stake in Xylem by 6.7% during the 1st quarter. Sei Investments Co. now owns 335,330 shares of the industrial products company’s stock valued at $28,590,000 after purchasing an additional 21,165 shares during the last quarter. Finally, Prudential PLC acquired a new position in Xylem during the 1st quarter valued at about $333,000. 83.57% of the stock is owned by institutional investors.

Insider Buying and Selling at Xylem

In other Xylem news, SVP Hayati Yarkadas sold 15,942 shares of the business’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $100.43, for a total transaction of $1,601,055.06. Following the sale, the senior vice president now owns 12,146 shares of the company’s stock, valued at approximately $1,219,822.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Patrick Decker sold 56,298 shares of the company’s stock in a transaction on Monday, March 13th. The shares were sold at an average price of $98.19, for a total value of $5,527,900.62. Following the transaction, the chief executive officer now owns 287,564 shares of the company’s stock, valued at $28,235,909.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Hayati Yarkadas sold 15,942 shares of the company’s stock in a transaction on Thursday, March 2nd. The stock was sold at an average price of $100.43, for a total transaction of $1,601,055.06. Following the completion of the transaction, the senior vice president now owns 12,146 shares of the company’s stock, valued at $1,219,822.78. The disclosure for this sale can be found here. Insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Morgan Stanley lifted their price target on Xylem from $105.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, January 18th. Stifel Nicolaus upgraded Xylem from a “hold” rating to a “buy” rating and boosted their target price for the stock from $115.00 to $124.00 in a research note on Tuesday, January 24th. Cowen boosted their target price on Xylem from $115.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 14th. Mizuho restated a “neutral” rating and issued a $105.00 target price on shares of Xylem in a research note on Wednesday, February 8th. Finally, StockNews.com began coverage on Xylem in a research note on Thursday, March 16th. They issued a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $114.80.

Xylem Trading Down 0.1 %

Shares of XYL stock opened at $104.64 on Tuesday. The company’s fifty day simple moving average is $102.23 and its two-hundred day simple moving average is $106.40. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.01 and a quick ratio of 1.44. Xylem Inc. has a 1 year low of $72.08 and a 1 year high of $118.58. The stock has a market capitalization of $18.90 billion, a price-to-earnings ratio of 51.04, a PEG ratio of 2.76 and a beta of 1.07.

Xylem (NYSE:XYL – Get Rating) last issued its earnings results on Thursday, May 4th. The industrial products company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.10. Xylem had a net margin of 6.53% and a return on equity of 16.63%. The business had revenue of $1.45 billion for the quarter, compared to analysts’ expectations of $1.35 billion. During the same quarter in the previous year, the firm posted $0.47 EPS. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. As a group, analysts anticipate that Xylem Inc. will post 3.24 earnings per share for the current year.

About Xylem

(Get Rating)

Xylem, Inc engages in the design, manufacture, and application of engineered technologies for the water industry. It operates through the following business segments: Water Infrastructure, Applied Water, and Measurement and Control Solutions. The Water Infrastructure segment focuses on the transportation, treatment and testing of water.